Nureca Limited , a company listed on both BSE and NSE, has announced that its Chief Financial Officer (CFO), Naresh Gupta, has withdrawn his resignation with immediate effect. This development comes less than a month after Gupta's initial resignation on October 11, 2025.

Resignation Withdrawal

According to the company's official statement, Gupta's decision to withdraw his resignation stems from the resolution of personal issues that had initially prompted his decision to step down. The company has informed that this matter will be formally noted by the Board of Directors in their upcoming meeting.

Timeline of Events

Additional Corporate Updates

In a separate but related development, Nureca Limited has also announced the closure of its trading window. This closure is in anticipation of a board meeting scheduled for November 10, 2025, which will discuss the potential buyback of company shares.

Trading Window Closure Details

These developments underscore the dynamic nature of corporate governance and the importance of transparent communication with shareholders and regulatory bodies. Investors and market watchers will likely keep a close eye on Nureca Limited's upcoming board meeting and any potential outcomes regarding the share buyback discussion.

Nureca Limited , a prominent player in the home healthcare and wellness sector, has received a significant regulatory green light from the Securities and Exchange Board of India (SEBI). The company announced that SEBI has granted approval for an exemption from Regulation 24(ii) of the Buy-Back Regulations, allowing Nureca to proceed with a share buyback while its merger scheme with wholly-owned subsidiary Nureca Technologies Private Limited is pending before the National Company Law Tribunal (NCLT).

Key Developments

• SEBI Approval: Granted
• Merger Scheme Approval: Board approved on May 20; Shareholders approved on June 16
• Merger Type: Internal restructuring involving no new equity issuance or change in shareholding pattern
• Buyback Participation: Promoters have committed not to participate, making it exclusive for public shareholders

Regulatory Context

The exemption granted by SEBI is from Regulation 24(ii) of the SEBI (Buy-Back of Securities) Regulations, 2018, which typically prohibits companies from announcing buybacks during pending schemes of arrangement. SEBI's decision to grant this exemption considers the nature of the merger as an internal restructuring that does not affect the company's public shareholding.

Implications for Shareholders

This development is particularly significant for Nureca's public shareholders. With the promoters abstaining from the buyback, the opportunity is exclusively available to public shareholders, potentially offering them an avenue to realize value in the near term.

Next Steps

Nureca's board of directors will consider the buyback proposal at an appropriate time. The company has assured compliance with all applicable regulations throughout the process.

Market Perspective

This move by Nureca Limited demonstrates a strategic approach to capital management while navigating regulatory requirements. The ability to proceed with a share buyback during a pending merger reflects the company's focus on shareholder value and its confidence in its financial position.

As the home healthcare and wellness sector continues to evolve, Nureca's actions may be indicative of broader trends in corporate strategy within the industry, balancing growth initiatives with shareholder returns.

Investors are advised to monitor further announcements from Nureca Limited regarding the specifics of the buyback program and the progress of the merger with Nureca Technologies Private Limited.